The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies. (14th March 2018)

• Record Type: Journal Article
• Authors: Schiavone, Stefania; Trabace, Luigia
• Is Part Of: CNS neuroscience & therapeutics. Volume 24:Number 6(2018)
• Page Start: 465
• Page End: 472
• Publication Date: 2018-03-14
• Subjects: animal model -- antioxidant -- apocynin -- first psychotic episode -- N‐acetylcisteine; Neuropharmacology -- Periodicals; Central nervous system -- Diseases -- Effect of drugs on -- Periodicals; 612.8
• DOI: 10.1111/cns.12847
• Languages: English
• ISSNs: 1755-5930

Abstract

Summary: Recent evidence highlighted a pathogenetic link between redox dysregulation and the early stages of psychosis. Indeed, an increasing number of studies have pointed toward an association between oxidative stress, both at central and peripheral levels, and first psychotic episode. Moreover, basal low antioxidant capacity has been shown to directly correlate with cognitive impairment in the early onset of psychosis. In this context, the possibility to use antioxidant compounds in first psychotic episode, especially as supplementation to antipsychotic therapy, has become the focus of numerous investigations on rodents with the aim to translate data on the possible effects of antioxidant therapies to large populations of patients, with a diagnosis of the first psychotic episode. In this review, we will discuss studies, published from January 1st, 2007 to July 31st, 2017, investigating the effects of antioxidant compounds on neuropathological alterations observed in different rodent models characterized by a cluster of psychotic‐like symptoms reminiscent of what observed in human first psychotic episode. A final focus on the effective possibility to directly translate data obtained on rodents to humans will be also provided.